CoChat

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer

Open access

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index; none of the 5 sources its claims cite is checked for support yet.

Abstract

In the phase III CodeBreaK 300 study, sotorasib 960 mg-panitumumab significantly prolonged progression-free survival (PFS) versus investigator's choice (trifluridine/tipiracil or regorafenib) in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer (mCRC). One hundred sixty patients were randomly assigned 1:1:1 to receive sotorasib 960 mg-panitumumab (n = 53), sotorasib 240 mg-panitumumab (n = 53), or investigator's choice (n = 54; crossover permitted after primary analysis). Overall survival (OS) analysis, a key secondary end point, although not adequately powered, was prespecified at 50% maturity (after approximately 80 deaths). In this study, we report the OS, updated overall response rates (ORRs), and data for safety. After a median follow-up of 13.6 months, 24, 28, and 30 deaths occurred in the sotorasib 960 mg-panitumumab, sotorasib 240 mg-panitumumab, and investigator's choice arms, respectively; updated objective response rates (ORRs; 95% CI) were 30.2% (95% CI, 18.3 to 44.3), 7.5% (95% CI, 2.1 to 18.2), and 1.9% (95% CI, 0.0 to 9.9), respectively. Compared with investigator's choice, the hazard ratios (HRs [95% CI]) for OS were 0.70 (95% CI, 0.41 to 1.18; two-sided P = .20) with sotorasib 960 mg-panitumumab and 0.83 (95% CI, 0.49 to 1.39; two-sided P = .50) with sotorasib 240 mg-panitumumab. No new safety signals were observed. Although not statistically significant, the observed OS HR and ORR along with prior PFS and safety findings support sotorasib 960 mg-panitumumab as a standard of care in patients with chemorefractory KRAS G12C mCRC.

Overview

CoChat Summary

TL;DR

In the phase III CodeBreaK 300 study, sotorasib 960 mg plus panitumumab did not significantly improve overall survival (OS) versus investigator’s choice in chemorefractory KRAS G12C-mutated metastatic colorectal cancer, with an OS hazard ratio of 0.70 (95% CI, 0.41 to 1.18; P = .20). The authors conclude that the OS trend, higher objective response rate, prior PFS benefit, and safety profile support sotorasib 960 mg-panitumumab as a standard of care in this population.

Key findings

  • At a median follow-up of 13.6 months, 82 deaths occurred: 24 in the sotorasib 960 mg-panitumumab arm, 28 in the sotorasib 240 mg-panitumumab arm, and 30 in the investigator’s choice arm. OS HRs versus investigator’s choice were 0.70 (95% CI, 0.41 to 1.18; two-sided P = .20) for sotorasib 960 mg-panitumumab and 0.83 (95% CI, 0.49 to 1.39; two-sided P = .50) for sotorasib 240 mg-panitumumab.
  • Median OS was not reached (95% CI, 8.61 to NE) with sotorasib 960 mg-panitumumab, 11.9 months (95% CI, 7.52 to NE) with sotorasib 240 mg-panitumumab, and 10.3 months (95% CI, 7.00 to NE) with investigator’s choice.
  • Updated ORRs were 30.2% (95% CI, 18.3 to 44.3) with sotorasib 960 mg-panitumumab, 7.5% (95% CI, 2.1 to 18.2) with sotorasib 240 mg-panitumumab, and 1.9% (95% CI, 0.0 to 9.9) with investigator’s choice; median DOR was 10.1 months (95% CI, 3.9 to NE) in the sotorasib 960 mg-panitumumab arm.
  • No new safety signals were observed. Grade ≥3 treatment-related adverse events occurred in 45.3%, 34.0%, and 45.1% of patients receiving sotorasib 960 mg-panitumumab, sotorasib 240 mg-panitumumab, and investigator’s choice, respectively.

Methods

  • Phase III CodeBreaK 300 randomized 160 adults with KRAS G12C-mutated chemorefractory metastatic colorectal cancer who were KRASG12C inhibitor naïve 1:1:1 to sotorasib 960 mg-panitumumab (n = 53), sotorasib 240 mg-panitumumab (n = 53), or investigator’s choice (n = 54; trifluridine/tipiracil n = 37, regorafenib n = 14).
  • OS was a key secondary end point, prespecified at 50% maturity (after approximately 80 deaths); ORR was assessed by blinded independent central review per RECIST v1.1.
  • Analysis used the intention-to-treat population; HRs and 95% CIs were estimated with a stratified Cox proportional hazards model, and P values were calculated using a stratified log-rank test.

Limitations

  • The paper states the study was not powered to detect a statistically significant OS difference because of the small sample size related to the rarity of this patient population.
  • The paper states that post-trial use of KRASG12C inhibitor plus EGFR inhibitor in 27.8% of patients in the investigator’s choice arm could have confounded OS results; an ad hoc sensitivity analysis adjusting for subsequent therapies of interest showed a stratified HR of 0.65 (95% CI, 0.28 to 1.37) for sotorasib 960 mg-panitumumab versus investigator’s choice.
  • The paper notes that some prespecified subgroup analyses had small sample sizes and wide CIs; it also states that because statistical significance for OS was not achieved, ORR per BICR was not formally tested.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1200/jco-24-02026

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIG 1. CONSORT diagram of patient disposition. For the sotorasib-panitumumab arms, data on patient numbers continuing treatment (treatment ongoing) represents continuing any component of the doublet for a patient. OS, overall survival.
FIG 1. CONSORT diagram of patient disposition. For the sotorasib-panitumumab arms, data on patient numbers continuing treatment (treatment ongoing) represents continuing any component of the doublet for a patient. OS, overall survival.CC BY-NC-ND · PubMed Central
FIG 2. OS of sotorasib-panitumumab versus investigator's choice. (A) Kaplan-Meier curves of OS for sotorasib 960 mg-panitumumab (full analysis set). (B) Kaplan-Meier curves of OS for sotorasib 240 mg-panitumumab (full analysis set). (C) Forest plot of sotorasib 960 mg-panitumumab treatment effect on OS in subgroup analyses. (D) Forest plot of sotorasib 240 mg-panitumumab treatment effect on OS in subgroup analyses. The dashed horizontal gray line indicates the median value. Vertical bars indicate censoring. Stratified Cox hazard ratio and stratified log-rank P value for sotorasib-panitumumab versus investigator's choice are provided. The intention-to-treat population included all patients who underwent random assignment. Hazard ratio was not estimated when there were fewer than 10 patients in either treatment arm in a subgroup. HR, hazard ratio; NE, not estimable; OS, overall survival.
FIG 2. OS of sotorasib-panitumumab versus investigator's choice. (A) Kaplan-Meier curves of OS for sotorasib 960 mg-panitumumab (full analysis set). (B) Kaplan-Meier curves of OS for sotorasib 240 mg-panitumumab (full analysis set). (C) Forest plot of sotorasib 960 mg-panitumumab treatment effect on OS in subgroup analyses. (D) Forest plot of sotorasib 240 mg-panitumumab treatment effect on OS in subgroup analyses. The dashed horizontal gray line indicates the median value. Vertical bars indicate censoring. Stratified Cox hazard ratio and stratified log-rank P value for sotorasib-panitumumab versus investigator's choice are provided. The intention-to-treat population included all patients who underwent random assignment. Hazard ratio was not estimated when there were fewer than 10 patients in either treatment arm in a subgroup. HR, hazard ratio; NE, not estimable; OS, overall survival.CC BY-NC-ND · PubMed Central
FIG A1. Multiple testing procedure for PFS and OS. OS, overall survival; PFS, progression-free survival.
FIG A1. Multiple testing procedure for PFS and OS. OS, overall survival; PFS, progression-free survival.CC BY-NC-ND · PubMed Central
FIG A2. OS of sotorasib-panitumumab versus investigator's choice adjusting for control patients receiving subsequent KRASG12C inhibitor plus EGFR antibody (full analysis set). EGFR, epidermal growth factor receptor; HR, hazard ratio; OS, overall survival; NE, not estimable.
FIG A2. OS of sotorasib-panitumumab versus investigator's choice adjusting for control patients receiving subsequent KRASG12C inhibitor plus EGFR antibody (full analysis set). EGFR, epidermal growth factor receptor; HR, hazard ratio; OS, overall survival; NE, not estimable.CC BY-NC-ND · PubMed Central
FIG A3. Swimmer plot of duration of response by BICR (responders in the full analysis set). BICR, blinded independent central review; BOR, best overall response; CR, complete response; OS, overall survival; PFS, progression-free survival; PR, partial response.
FIG A3. Swimmer plot of duration of response by BICR (responders in the full analysis set). BICR, blinded independent central review; BOR, best overall response; CR, complete response; OS, overall survival; PFS, progression-free survival; PR, partial response.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 5 Not checked · 21 Own results and interpretations

9 more claims

Create a free account to see all 26 claims and to verify the 5 references still open.

See all claims — free account
  • It may state two separate claims as one. 7
  • Probably not a substantial claim. 5

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Cited by

See all 67

Metadata

Authors
Pietrantonio, F., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T. W., Kuboki, Y., Meriggi, F., Cunningham, D., Yeh, K.-H., Chan, E., Chao, J., Tran, Q., Cremolini, C., & Fakih, M.
Affiliations
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
  • Università Cattolica del Sacro Cuore (IT)
  • National Hospital Organization Kyushu Cancer Center (JP)
  • Stiftung Charité (DE)
  • Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
  • Université Paris Cité, SIRIC CARPEM Comprehensive Cancer Center, Department of Gastroenterology and Digestive Oncology, Hopital Européen Georges Pompidou, Paris, France
  • National and Kapodistrian University of Athens (GR)
  • GI Oncology Department & Translational Medicine Laboratory, INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico, Mexico
  • Asan Medical Center (KR)
  • National Cancer Center Hospital East (JP)
  • Fondazione Poliambulanza Istituto Ospedaliero (IT)
  • Royal Marsden Hospital (GB)
  • National Taiwan University (TW)
  • Amgen (United States) (US)
  • University of Pisa (IT)
  • City Of Hope National Medical Center (US)
Corresponding author
Fakih, Marwan
Venue
Journal of Clinical Oncology
Published
2025-07
Volume
43
Issue
19
Pages
2147-2154
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W4409350464
Cited by
51
References
8
Citations by year
2026: 39 · 2025: 12
FWCI
20.95
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Journal of Clinical Oncology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc-nd)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
Funders
Amgen
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
sotorasib, panitumumab, KRAS G12C, metastatic colorectal cancer, overall survival, progression-free survival, objective response rate, trifluridine/tipiracil, regorafenib, EGFR inhibition, drug safety
MeSH terms
Panitumumab, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Mutation, Phenylurea Compounds, Piperazines, Pyridines, Pyrimidines, Sulfonamides, Thymine, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.